Erectile Dysfunction Drugs Market Share

Global Erectile Dysfunction Drugs Market Overview

Erectile Dysfunction Drugs Market Size was valued at USD 4.2 billion in 2022. The Erectile Dysfunction Drugs market industry is projected to grow from USD 4.4 Billion in 2023 to USD 6.65 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 6.80% during the forecast period (2024 - 2030).The rising prevalence of sedentary behaviour and the burden of lifestyle diseases are the key market drivers enhancing the market growth.

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

September 2023: New Delhi-based contract manufacturing and development organization (CDMO), Akums Drugs and Pharmaceuticals, has launched a development in healthcare — the Tamsulosin + Tadalafil Capsule — to the Indian market. The development of combined therapy, offered in a fixed dose grouping within a hard gelatin capsule, implies a crucial achievement for the company. Considerably, Akums has become the first CDMO to gain approval for an extraordinary formulation of Tamsulosin 0.4/0.4mg + Tadalafil 2.5/5mg, as authorized by the Drug Controller General of India (DCGI). Tamsulosin is a discerning alpha1A-adrenergic receptor antagonist. The impacts of Tamsulosin are focused on the efficient muscle receptors of the urethra and prostate. Preventing this receptor loosens up the smooth muscle of the urethra and bladder to regulate urine flow. It is mainly utilized when an enlarged prostate impedes normal urine flow and bladder emptying. In tandem, the method of action for Tadalafil centers on the inhibition of PDE5, a vital enzyme placed in the vascular smooth muscle cells of the corpus cavernosum. By inhibiting cGMP hydrolysis, Tadalafil advances cGMP accumulation and the relaxation of vascular smooth muscle, enabling the growth of a physiologically induced erection contingent upon sexual stimulation.

August 2023: The latest research has associated erectile dysfunction drugs with a lowered risk of a common form of dementia. Men recommended erectile dysfunction drugs like Cialis and Viagra were 18 percent less likely to advance Alzheimer's disease, a new study has discovered. The results offer some hope that these drugs could be repurposed to restrict a common form of dementia, but more clinical trials are required to determine whether there is a causal link. The new UK research had around 270,000 men who were detected with erectile dysfunction and had no rational challenges at the beginning of the research.

Erectile Dysfunction Drugs Market Trends

• Growing Prevalence of spine degeneration to boost market growth

The sedentary lifestyle trend and the stress it causes, the growing senior population, and the correlation between erectile dysfunction and diabetes and heart disease are some factors propelling the market for erectile dysfunction (ED) medications. A sedentary lifestyle, drunkenness, and smoking significantly increase the likelihood of erectile dysfunction. Alcohol use, poor glycemic control, age, and duration of diabetes were all discovered to be predictors of erectile dysfunction, according to a study published in BMC Endocrine Disorders in July 2021. In 2021, it was found that erectile dysfunction affected 72.2% of persons worldwide. Age, diabetes, alcohol use, and poor glycemic control were found to have an impact on erectile dysfunction, which is what is causing the market to rise. The government-imposed lockdown in 2020, according to the University of Pittsburgh's School of Medicine, caused a significant increase in erectile dysfunction medicine sales. Sales of Cialis (Tadalafil), the most popular ED medication, increased significantly in the United States. The demand for erectile dysfunction medications was also encouraged by other reasons, such as simple access to ED medications. Nowadays, several drugs are used to treat erectile dysfunction, including avanafil (Stendra), vardenafil (Levitra), sildenafil (Revatio), and tadalafil (Levitra, Staxyn).

Generic sildenafil is frequently sold far cheaper than Viagra, which typically costs about USD 70 per pill, depending on the dose. As a result, the availability of affordable pharmaceuticals may increase the rate of prescriptions and expand the market. The prevalence of ED is noticeably rising with age due to coexisting diseases, including diabetes, obesity, and others. Males are also more likely to acquire the infection from hormonal, neurological, vascular, and medication-related causes. Therefore, such medical condition has enhanced the Erectile Dysfunction Drugs market CAGR across the globe in the recent years.

However, With the increase in unhealthy lifestyles, obesity, diabetes, and cardiovascular diseases are on the rise. Over time, this causes problems like ED as people age is another factor driving the growth of the Erectile Dysfunction Drugs market revenue.

Erectile Dysfunction Drugs Market Segment Insights

Erectile Dysfunction Drugs Type Insights

The Erectile Dysfunction Drugs market segmentation, based on Drugs, includes viagra, cialis, stendra/spedra, Zydena, Vitaros, and others. The viagra segment held the majority share in 2022, contributing to around ~35% of the Erectile Dysfunction Drugs market revenue. Several businesses are currently engaging in various strategic activities to grow their market share, including research alliances, agreements, and partnerships. For instance, Pfizer, Inc. and Digital Men's Clinic Roman struck a supply arrangement in January 2020 to give Roman members access to a generic form of Viagra. This supply deal is anticipated to accelerate the segment's growth.

Zydena was the fastest-growing segment due to the widespread usage and accessibility of ED medications, including Mvix (mirodenafil), Helleva (lodenafil carbonate), and others used to treat adult patients with erectile dysfunction. Increased acceptance of over-the-counter ED medications gives patients easy access. For instance, Tadalafil MAXON from the prescription to over-the-counter (OTC) category was approved for marketing authorization by Adamed, the first Polish business, in February 2022. Thus, the release of such goods could increase the use of ED medications.  

Erectile Dysfunction Drugs End User Insights

Based on End Users, the Erectile Dysfunction Drugs market segmentation has been segmented into Hospital pharmacies, Retail Pharmacies, Online Pharmacies, and others. Retail Pharmacies held the most significant segment share in 2022, the drug's ease of access and the market's increasing ED cases. For many patients who are wary of approaching a retail pharmacy store to buy medications for erectile dysfunction and other sexual wellness goods, retail pharmacies are a blessing in disguise.

The fastest-growing segment in the Erectile Dysfunction Drugs market data is Online Pharmacy. The rising prevalence of erectile dysfunction tends to encourage the use of alternative treatments for efficient and quicker outcomes.

Figure 1: Erectile Dysfunction Drugs Market, by End User 2022 & 2030 (USD Billion)

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

Erectile Dysfunction Drugs Regional Insights

By Region, the study provides the market insights into North America, Europe, Asia-Pacific and Rest of the World. North America Erectile Dysfunction Drugs market accounted for USD 1.92 billion in 2022 and is expected to exhibit a significant CAGR growth during the study period. This is because to the high prevalence of sickness, the robust healthcare system, and the acceptance of novel therapeutic products. Lupin gained approval from the U.S. FDA in March 2022 to market its ANDA for sildenafil (10 mg/mL oral suspension) as a generic alternative to Revatio from Viatris Specialty LLC. Patient compliance may rise as a result of the availability of reasonably priced generic medications, which would grow the market's consumer base and income. according to a report from the National Institute of Diabetes and Digestive and Kidney Diseases, approximately 30 million men in the US were plagued by ED in 2021. In addition, the nation has the highest rate of self-reported ED, which is anticipated to fuel market expansion throughout the projected decade.

Further, the major countries studied in the market report are: The U.S, Canada, Germany, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.

 Figure 2: ERECTILE DYSFUNCTION DRUGS MARKET SHARE BY REGION 2022 (%)

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

Europe Erectile Dysfunction Drugs market accounts for the second-largest market share. The market expansion in this region is projected to be fueled by the rising elderly population as well as many product launches by major market competitors. Further, the Germany Erectile Dysfunction Drugs market held the largest market share, and the UK Erectile Dysfunction Drugs market was the fastest growing market in the European region/

The Asia-Pacific Erectile Dysfunction Drugs Market is expected to grow at the fastest CAGR from 2022 to 2030. The introduction of new items has contributed to the region's growth. For instance, iX Biopharma stated in May 2020 that it would provide Wafesil and Silcap in Australia via telemedicine to treat an adult patient with erectile dysfunction. Moreover, China Erectile Dysfunction Drugs market held the largest market share, and the India Erectile Dysfunction Drugs market was the fastest growing market in the Asia-Pacific region.

Erectile Dysfunction Drugs Key Market Players & Competitive Insights

The industry's leading companies are investing significantly in R&D to expand their product portfolios, which will fuel future growth in the erectile dysfunction drugs market. In addition, market participants are introducing new products, entering into contracts, acquiring other companies, raising investments, and working with other organizations, among other significant market developments, to expand their footprint. To grow and thrive in a fiercely competitive and growing market climate, competitors in the erectile dysfunction drugs industry must provide affordable products.

Producing locally to save costs on overhead is one of the leading business methods used by companies in the erectile dysfunction drugs trade to benefit the consumer and grow the market sectorIn recent years, Erectile Dysfunction Drugs industry has provided medicine with some of the most significant benefits. In the Erectile Dysfunction Drugs market, major players such as Laboratorios Rubio S.A., Adamed pharma s.a and others are working on expanding the market demand by investing in research and development activities.

The company Laboratorios Rubio SA produces and sells medical supplies. The company offers various medications, dressings, dialysis bags, diagnostic tools and tests, and food supplements. In May 2022, Aspargo Laboratories, Inc. purchased the prescription brand Bandol from the Spanish specialty pharmaceutical company Laboratorios Rubio S.A.

Also, With over 30 years of expertise, Adamed is a pharmaceutical and biotechnology company that was established on the basis of Polish scientific advancements and a patent portfolio. In February 2022, The first marketing authorization for over-the-counter tadalafil has ever been awarded to Polish pharmaceutical company Adamed Pharma. Tadalafil MAXON was recently moved from the Rx category to the OTC category by the President of the Office for Registration of Medicinal Goods, Medical Devices, and Biocidal Products. On 01.02.2022, the reclassification decision became effective.

Key Companies in the Erectile Dysfunction Drugs market includes

• 
  

  Pfizer Inc. (U.S)

  
  


• 
  

  Apricus Biosciences Inc. (U.S).

  
  


• 
  

  Bayer AG (Germany)

  
  


• 
  

  Dong–A Pharmaceutical Co. Ltd. (South Korea)

  
  


• 
  

  S.K. Chemicals Co. Ltd. (South Korea)

  
  


• 
  

  Eli Lily & Co. (U.S)

  
  


• 
  

  Apricus Biosciences Inc. (U.S)

  
  


• 
  

  Cristalia Produtos Quimicos Farmaceuticos Ltd.

  
  


• 
  

  Meda Pharmaceuticals, Inc.

  
  


• 
  

  S.K. Chemicals Co. Ltd.

  
  


• 
  

  Vivus Inc.

  
  


• 
  

  Teva Pharmaceutical Industries Ltd, among others

  
  

Erectile Dysfunction Drugs Industry Developments

September 2021:To treat male erectile dysfunction in China, Wafesil, a sublingual sildenafil wafer, was licenced, supplied, and distributed by iX Biopharma through its wholly-owned subsidiary.

September 2021:Almus introduced 50mg film-coated Almus Erectile Dysfunction Relief tablets to the UK pharmaceutical market.

Erectile Dysfunction Drugs Market Segmentation

Erectile Dysfunction Drugs Type Outlook

• 
  

  Viagra

  
  


• 
  

  Cialis

  
  


• 
  

  Stendra/Spedra

  
  


• 
  

  Zydena

  
  


• 
  

  Vitaros

  
  

Erectile Dysfunction Drugs End User Outlook

• 
  

  Hospital Pharmacy

  
  


• 
  

  Retail Pharmacy

  
  


• 
  

  Online Pharmacy

  
  

Erectile Dysfunction Drugs Regional Outlook

• North America
  
  
  
  • US
  
  
  • Canada
  
  
  
  


• Europe
  
  
  
  • Germany
  
  
  • France
  
  
  • UK
  
  
  • Italy
  
  
  • Spain
  
  
  • Rest of Europe
  
  
  
  


• Asia-Pacific
  
  
  
  • China
  
  
  • Japan
  
  
  • India
  
  
  • Australia
  
  
  • South Korea
  
  
  • Australia
  
  
  • Rest of Asia-Pacific
  
  
  
  


• Rest of the World
  
  
  
  • Middle East
  
  
  • Africa
  
  
  • Latin America